Constipation and laxative use have been hypothesized to increase colorectal cancer (CRC) risk, but existing epidemiologic studies have been inconclusive. To address this issue, the authors prospectively examined the association between CRC incidence and constipation, non-fi ber laxative use, and fi ber laxative use among 75,214 participants of the VITamins And Lifestyle study.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common incident cancer in the United States, with an estimated 142,820 new cases expected to have occurred in 2013 ( 1 ) . In the early 1970s, Burkitt ( 2 ) hypothesized that infrequent bowel movements increased CRC risk by increasing both the concentrations of carcinogens in the stool and the duration for which these carcinogens are in contact with the colonic mucosa. Multiple studies have attempted to address this topic, with a meta-analysis of case -control studies conducted in 1993 ( 3 ) and several later case -control studies ( 4, 5 ) reporting that infrequent bowel movements or constipation was associated with an increased risk for CRC. However, case -control studies are prone to bias as disease status may have infl uenced recall of actual or perceived bowel motility. Although several cohort studies have also reported a positive association between constipation and CRC ( 6, 7 ) , others have shown no association ( 8 -10 ) , or even inverse associations ( 6, 11 ) between infrequent bowel movements and CRC risk. However, many of these studies were limited by small sample sizes and short follow-up periods. In addition, results may have been further obfuscated by the complexity of characterizing bowel motility as well as the widespread use of laxatives.
Laxatives, used by roughly 20 % of the US population, have also been hypothesized to increase colon cancer risk. Stimulant purgatives, the most commonly used laxative, have been found to demonstrate mutagenic and carcinogenic eff ects in both
METHODS

Study population
As reported previously ( 17 ) , the VITamins And Lifestyle study is a prospective study designed to investigate the association between vitamins, minerals, and other dietary supplements and cancer risk. Briefl y, men and women aged 50 -76 years at baseline who lived in the 13-county region in western Washington State covered by the Surveillance, Epidemiology, and End Results cancer registry were eligible to participate. Between October 2000 and December 2002, baseline questionnaires were mailed to 364,418 individuals who were identifi ed by a commercial mailing list. Among them, 77,719 (21.3 % ) individuals returned questionnaires and satisfi ed eligibility requirements.
Exclusion criteria for these analyses included patients with the following: a history of CRC at baseline ( n = 971) or with missing baseline CRC information ( n = 213); a history of ulcerative colitis or Crohn ' s disease ( n = 1,030); intestinal polyposis ( n = 273); diagnosis with in situ CRC over the period of follow-up ( n = 12); cancer noted on death certifi cate only with no diagnosis date available ( n = 1); and a diagnosis with CRC of certain rare morphologies (listed below, n = 33). In addition, individuals with missing information on all four exposure variables ( n = 15) were excluded, leaving 75,214 patients for analyses. Th e above-listed exclusions are not mutually exclusive, and hence individuals may have been excluded for more than one reason. Study participants provided informed consent and study procedures were approved by the Fred Hutchinson Cancer Research Center Institutional Review Board.
Exposure assessment
Vitamins and Lifestyle participants completed a self-administered, sex-specifi c, 24-page questionnaire on supplement use, medication use, health history, risk factors, and diet.
Closed-ended questions were used to ascertain 10-year average history of constipation (Over the past 10 years, how oft en did you feel constipated enough to take something, such as a laxative, enema, or prunes?) and non-fi ber laxative use (Over the past 10 years, about how many times have you taken non-fi ber laxatives (such as Ex-lax, Correctol, or milk of magnesia)?). Response options (never or less than once per year, 1 -4 times per year, 5 -11 times per year, 1 -3 times per month, or 1 time per week or more) were then categorized into three groups by combining the last three categories. Bowel movement frequency, which was ascertained by asking participants a closed-ended question (How oft en do you usually have a bowel movement?), was combined into four categories ( < 5 times per week, 5 -6 times per week, 1 time per day, and 2 or more times per day).
Fiber laxative use was ascertained by asking separate questions on frequency and duration of use of " fi ber products such as Metamucil, Citrucel, FiberCon, or Fiberall " in the 10-year period before baseline. Fiber laxative use was then categorized into three groups: high use (4 + days per week for 4 + years), low use ( < 4 days per week odds ratio (OR) < 4 years), or no use. Th ese categories were created a priori so that the highest level of exposure is defi ned by high frequency (4 + days per week) and substantial duration (4 + years) of use.
Participants also reported on personal characteristics as part of the baseline questionnaire, including age, sex, ethnicity, education, height, weight, dietary intake, recreational physical activity, cigarette smoking, alcohol consumption, family history of cancer, and medical history. Dietary intakes were assessed using a semiquantitative food frequency questionnaire, adapted from instruments developed for the Women ' s Health Initiative and other studies ( 18 -20 ) . Participants reported their usual frequency and portion size (small, medium, or large relative to a given portion size and to photographs of portion sizes) of 120 foods and beverages consumed during the year before baseline. Body mass index was calculated from a self-report of height and weight. Recreational physical activity was measured as average total metabolic equivalent hours per week over the past 10 years, based on the reported years, frequency, and estimated energy expenditure for diff erent moderate / vigorous activities.
Ascertainment of case status, site, and stage
Cohort members were followed up for incidence of CRC (ICD-O-3 codes of 18.0 -20.9) from enrollment to 31 December 2008, by linking the study cohort to the western Washington Surveillance, Epidemiology and End Results cancer registry. Aft er excluding in situ cases, carcinoid tumors, neuroendocrine carcinomas, and lymphomas, there were 558 eligible invasive cancers of the colon and rectum. Stage was based on Surveillance, Epidemiology, and End Results stage, which defi nes localized cancer as cancer that is limited to the organ in which it began, regional as beyond the original site to nearby lymph nodes or organs and tissues, and distant as cancer that has spread to distant organs or distant lymph nodes. Colon cancer cases included those with ICD-O-3 codes of 18.0 -18.9 and rectal cancer cases were those with ICD-O-3 codes of 19.9 and 20.9. Cases were followed up until date of CRC diagnosis and non-cases were censored at whichever occurred earlier: date of death (6.7 % ), date of emigration out of the Surveillance, Epidemiology, and End Results catchment area (5. state of Washington were identifi ed by linkage to the state death fi le, whereas emigrations out of area were identifi ed by linkage to the National Change of Address System and by telephone calls and mailings.
Statistical analysis
Logistic regression was used to calculate ORs with 95 % confi dence intervals (95 % CI) to evaluate associations between baseline study participant characteristics and laxative use.
Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95 % CIs for the associations of bowel habits and laxative use with the risk for CRC. Age was the time metric in regression models, with participants entering at the age of completing the baseline questionnaire and exiting at their age at the end of follow-up. P -value for trend was modeled by treating the categorical exposure variable as continuous.
Covariates included in multivariate analyses were selected a priori and included factors associated with CRC. Th e multivariate model included the following covariates: age, sex, race / ethnicity, education, body mass index (kg / m 2 ), physical activity, smoking history, energy intake, total calcium intake, alcohol consumption, multivitamin use, dietary fi ber intake, fruit / vegetable intake excluding potatoes, red / processed meat intake, and hormone replacement therapy, as well as aspirin use and non-aspirin nonsteroidal anti-infl ammatory drug use. Analyses also included adjustment for family history of CRC among fi rst-degree relatives, history of sigmoidoscopy / colonoscopy in the 10 years before baseline, and history of polyp removal. In addition, HRs were estimated with models mutually adjusted for all exposure variables (constipation, bowel movement frequency, fi ber laxative use, and non-fi ber laxative use).
Stratifi ed analyses were performed to examine the association between laxative use and CRC risk by sex. P -values for interaction by sex were calculated by including a single cross-product term between laxative use, modeled as a continuous categorical variable, and sex in the unstratifi ed, mutually adjusted multivariate model.
We also evaluated heterogeneity of the laxative -CRC association by cancer site (colon vs. rectum) and cancer stage (local vs. regional / distal) at the time of diagnosis. Logistic regression limited to cases was used to determine the statistical signifi cance of subsite-and stage-specifi c diff erences. In addition, a sensitivity analysis, which excluded all cases diagnosed within 1 year of follow-up, was performed to address the possibility that preclinical CRC may infl uence bowel habits and laxative use. Th e 1-year follow-up period was selected as CRC diagnoses usually occur within 1 year of onset of symptoms ( 21, 22 ) .
All reported P -values are two-sided, and a P -value < 0.05 was considered statistically signifi cant. All analyses were carried out using STATA 11 (StataCorp, College Station, TX).
RESULTS
Selected characteristics of VITamins And Lifestyle participants as well as age-and sex-adjusted ORs and 95 % CIs for the association between these characteristics and fi ber and non-fi ber laxative use are given in Table 1 . Increasing age, female sex, history of colonoscopy, history of polyp removal, aspirin / nonsteroidal anti-infl ammatory drug use, and hormone replacement therapy use were positively associated with both fi ber and non-fi ber laxative use. Education, moderate / vigorous physical activity, dietary fi ber intake, and fruit and vegetable consumption were positively associated with fi ber laxative use and inversely associated with non-fi ber laxative use. Alcohol consumption was less common in those who used non-fi ber and fi ber laxatives. Bowel movement frequency was inversely related to non-fi ber laxative use. Although constipation was positively associated with both fi ber and non-fi ber laxative use, the association was more pronounced for non-fi ber laxative use.
Participants were followed up for a total of 494,902 person-years. Cancer cases contributed 1,948 person-years, whereas controls contributed 492,954 person-years.
Associations of bowel habits and laxative use with CRC risk are presented in Table 2 . Constipation and bowel movement frequency were not statistically signifi cantly associated with CRC risk in either the multivariate model adjusted for covariates or in the fully adjusted model, which included covariates as well as the four interrelated main exposures. Results for non-fi ber and fi ber laxative use were similar in the multivariate and fully adjusted models. In the full, mutually adjusted model, both low (1 -4 times per year on average over the past 10 years) and high ( ≥ 5 times per year) non-fi ber laxative use over the prior 10 years was associated with 43 -49 % increase in CRC risk relative to use less than once a year (HR = 1.49, 95 % CI: 1.04 -2.14; HR = 1.43, 95 % CI: 0.82 -2.48, respectively); although this is not a monotonic trend, there was a statistically signifi cant trend across the three groups ( P trend = 0.05). High fi ber laxative use over the past 10 years ( ≥ 4 days per week and ≥ 4 years) vs. none was associated with a statistically signifi cant decrease in CRC risk (HR = 0.44, 95 % CI: 0.21 -0.95); however, there was no risk reduction for low fi ber laxative use (HR = 1.17, 95 % CI: 0.82 -1.68) and the test for trend was nonsignifi cant ( P trend = 0.19).
Tables 3 -5 present analyses of the fi ndings related to the two types of laxative use stratifi ed by sex, anatomic subsite, and cancer stage at diagnosis, respectively. Th e association between high non-fi ber laxative use in the 10 years before baseline and increased cancer risk was more apparent for men than for women, for colon cancer (vs. rectal) and for local (vs. regional / distant) CRC, although the diff erences were not statistically signifi cant (all P interaction > 0.10). Th e inverse association between fi ber laxative use and CRC risk was similar for men and women, colon and rectum, and local and regional / distant disease, with no evident heterogeneity (all P interaction > 0.47). Finally, the risk reduction associated with high fi ber laxative use was similar among those in the lower half of dietary fi ber intake (HR = 0.54; 95 % CI: 0.20 -1.47) and those in the upper half (HR = 0.36, 95 % CI: 0.11 -1.15; P interaction = 0.26) (data not shown).
In a sensitivity analysis, the associations between bowel habit, laxative use, and CRC risk remained virtually unchanged aft er excluding cases diagnosed within 1 year of follow-up. 
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DISCUSSION
Results from this study do not provide evidence of an association between bowel movement frequency or constipation and CRC risk. Th e association between laxative use and CRC risk varied by laxative type: use of non-fi ber laxatives was associated with a signifi cantly increased risk for CRC, whereas high use of fi ber laxatives was associated with decreased risk. Th ere was no evidence of diff erential eff ects by sex, cancer site, or cancer stage. However, the stratifi ed results in Tables 3 -5 led to small numbers in some cells and limited power to detect main laxative eff ects within subgroups or to detect signifi cant interactions. Although a meta-analysis of case -control studies ( 3 ) and several later case -control studies ( 4,23 -25 ) reported that infrequent bowel movements or increased constipation were positively associated with CRC risk, case -control studies are prone to selection and recall bias. Furthermore, the retrospective assessment of bowel habits in case -control studies is subject to issues of reverse causality, as changes in constipation frequency and bowel motility may be symptoms of colon cancer. Finally, not many studies made mutual adjustment for bowel movement frequency and laxative use in their models despite the possibility that use of laxatives to treat constipation, rather than constipation itself, might potentially increase the risk for CRC. Consistent with these concerns, several cohort studies, including the Miyagi cohort study, the Nurses ' Health Study, the Health Professionals Follow-Up Study, and the Japan Public Health Center Prospective Study ( 6 -9,14 ) , as well as conclusions from a systematic review on constipation, bowel movement frequency, and CRC risk (26) , have not found associations between bowel motility and CRC risk. However, contrary to our fi ndings, the Japan Collaborative Cohort Study found infrequent bowel movement to be associated with increased risk (women reporting a bowel movement every 6 days or less vs. ≥ 1 per day, incidence rate ratios = 2.47, 95 % CI: 1.01 -6.01) (6) , whereas the Netherlands Cohort Study on Diet and Cancer reported that constipation and Abbreviations: BMI, body mass index; CI, confi dence interval; CRC, colorectal cancer; HR, hazard ratios; NSAID, nonsteroidal anti-infl ammatory drug. a n : number after adjustment for age and sex. Adjusted for: age, sex, race / ethnicity, BMI, physical activity, education, fi ber, calcium, fruit and vegetable intake, red / processed meat intake, alcohol consumption, smoking, NSAID use, aspirin use, family history of CRC, colonoscopy / sigmoidoscopy screening, history of polyp removal, hormone replacement therapy use (among women), and caloric intake. c Adjusted for: age, sex, race / ethnicity, BMI, physical activity, education, fi ber, calcium, fruit and vegetable intake, red / processed meat intake, alcohol consumption, smoking, NSAID use, aspirin use, family history of CRC, colonoscopy / sigmoidoscopy screening, history of polyp removal, hormone replacement therapy use (among women), and caloric intake, laxative use, fi ber laxative use, bowel movement frequency, and constipation.
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Although many previous cohort studies failed to fi nd an association between laxative use and CRC risk ( 8, 15 ) , results may have been obscured by the fact that no distinction was made between stimulants and other laxatives. In vitro studies suggest that anthranoids, a type of stimulant laxative, have mutagenic and genotoxic eff ects, whereas animal studies have demonstrated that anthranoids increase cell proliferation activity ( 13 ) . Case -control studies examining stimulant laxatives have found that use was positively bowel movement infrequency were associated with decreased CRC risk (bowel movements every 2 days or less vs. 1 time per day -HR = 0.72, 95 % CI: 0.52 -1.01, P trend < 0.001; constipation: sometimes or more oft en vs. never -HR = 0.76, 95 % CI: 0.58 -0.98, P trend = 0.02) ( 11 ) . Th us, although our fi ndings do not support the hypothesis on bowel motility and CRC risk proposed by Burkitt, our null results are consistent with those observed in most cohort studies and the meta-analysis. ( 4, 27 ) . Previous studies examining the association between laxative use of any type and CRC by sex have yielded mixed results, with some reporting no interaction ( 7, 23 ) and others reporting a statistically nonsignifi cant stronger association in women than in men ( 23, 28, 29 ) , providing little support for our fi nding of an apparent stronger increased risk for non-fi ber laxative use among men. However, there was no evidence of formal eff ect modifi cation by sex in the current study. Our fi ber laxative results are similar to two previously published case -control studies: one that found that high fi ber laxative use was inversely associated with CRC risk (fi ber laxative users vs. nonusers, OR = 0.58, 95 % CI: 0.32 -1.05) ( 23 ) and another that found that all commercial laxatives, except fi ber laxatives, appeared to be associated with increased CRC risk (fi ber laxatives, ≥ 350 lifetime uses vs. no regular use, OR = 0.6, 95 % CI: 0.2 -2.1) ( 4 ). In contrast, our fi ndings are not consistent with two randomized controlled trials of fi ber supplementation and colorectal adenoma recurrence, one of which found no eff ect of supplementation with a high wheat-bran-fi ber cereal ( 30 ) , and another that found an adverse eff ect on adenoma recurrence with supplementation of ispaghula husk ( 31 ) . However, experimental and observational data provide biologic evidence that a high dietary fi ber intake is associated with decreased CRC risk by diluting carcinogens, binding carcinogenic secondary bile acids, and providing an important metabolic substrate (butyrate) to colonic cells as a result of bacterial fermentation ( 32 ) . In addition, dietary fi ber may reduce CRC by producing short-chain fatty acids as well as normalizing cell proliferation and diff erentiation ( 33 ) .
Given that we found CRC risk to be dependent on laxative type, fi ndings from the current study would help to explain the inconsistencies in previous studies that grouped all laxative types together. However, further research by laxative subtype is needed, as non-fi ber laxatives encompass a broad range of agents that may be diff erentially associated with CRC risk.
Th e strengths of this study include the large cohort size, the essentially complete follow-up, and the measurements of covariates, which allowed for adjustment of multiple CRC risk factors. In addition, the prospective design of the study allowed data on bowel habit and laxative use to be collected before diagnosis of CRC, thus reducing bias resulting from reverse causality. In addition, exclusion of cancer cases identifi ed during the fi rst year of follow-up did not impact point estimates, a fi nding that supports the likelihood that reverse causality did not infl uence the results. Finally, our fi ndings for laxative use and CRC by stage suggest that the associations were not stronger for those with more advanced stage, as would be expected if disease stage aff ected laxative use.
Study limitations include use of self-reported measures, which may have led to misclassifi cation, as well as lack of detailed information on stool consistency. Previous studies have found that loose stools were related to an increased risk for CRC ( 9, 10 ) . As such, more specifi c measures of bowel function, such as stool weight and consistency, may provide additional information related to the eff ect of bowel function on CRC risk. In addition, as described in the results section above, our fi ndings for both fi ber laxative use and non-fi ber laxative use did not show monotonic trends across none, low, and high use . Although the associations between laxative use and CRC persisted aft er adjusting for covariates, fi ndings may still be attributable to residual or unmeasured confounding and not to casual associations. Furthermore, the stratifi ed analyses of the associations between laxative use and CRC risk were limited in power, as case numbers in the highest exposure groups were small and thus need replication. In addition, confounding by indication is a concern in any epidemiologic study of drugs. Specifi cally, it is possible that more severe constipation was more likely treated by non-fi ber laxatives, and it is the severe constipation rather than the non-fi ber laxative use that led to the increased risk. However, constipation was not a risk factor for CRC in this study, and adjusting for constipation had little impact on the risk estimates associated with use of fi ber or non-fi ber laxatives. Furthermore, we found associations with CRC risk to be in opposite directions for fi ber and non-fi ber laxative use, even though both are associated with constipation. Nonetheless, it is diffi cult to defi ne separately constipation and laxative use, and therefore diffi cult to have full confi dence in whether the drug or its indication is driving the association.
In summary, we observed that non-fi ber laxative use was associated with an increased risk for CRC, whereas fi ber laxative use was inversely associated with risk. However, uncertainty remains about our fi ndings because of lack of monotonic dose -response trends for our results, the possibility of residual confounding in observational epidemiologic studies, and lack of consistent support for our results from experimental studies, including one trial that found an adverse eff ect of supplemental fi ber on adenoma recurrence ( 31 ) . Th us, further research of specifi c laxative types is needed before conclusions can be drawn about recommending any specifi c type of laxative to patients with constipation.
